# First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors

> **NCT05759949** · PHASE1 · COMPLETED · sponsor: **Relay Therapeutics, Inc.** · enrollment: 41 (actual)

## Conditions studied

- PIK3CA Mutation
- Solid Tumor, Adult
- HER2-negative Breast Cancer
- Breast Cancer
- Metastatic Breast Cancer
- Advanced Breast Cancer
- Unresectable Solid Tumor
- Hormone Receptor Positive Tumor

## Interventions

- **DRUG:** RLY-5836
- **DRUG:** Fulvestrant
- **DRUG:** Palbociclib
- **DRUG:** Ribociclib
- **DRUG:** Abemaciclib

## Key facts

- **NCT ID:** NCT05759949
- **Lead sponsor:** Relay Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-29
- **Primary completion:** 2025-03-18
- **Final completion:** 2025-04-11
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2025-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05759949

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05759949, "First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05759949. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*